Technology and Experience

Thanks to our progressive technology and years of experience we are able to offer a unique biological preventive measure at the highest level.

TICEBA - Technology and experience - Picture 01TICEBA - Technology and experience - Picture 02


Ventilation System

In order to protect the skin tissue and the stem cells from pathogenic agents from the air, TICEBA has a ventilation and air conditioning system that is especially adapted to our needs. In addition, the elaborated filtering technology is providing for contaminations to be extracted from the air and the stem cells are therefore protected from contamination during processing.


Independence

Our cryostorage tanks that are used to freeze the stem cells may be run independently from power supply and are therefore not affected by power blackouts. The liquid nitrogen needed for storage is refilled automatically. If power supply is cut out, nitrogen may be refilled manually. Our staff is available 24 hours a day, 365 days a year for this purpose in the case of emergency. This guarantees the required temperature of -196°C (-384.8° Fahrenheit) at all times.


24/7 Alarm System

The monitoring system developed especially for TICEBA is active 24 hours / 7 days a week and registers the smallest changes and deviations. In the case of emergency, qualified employees who immediately take care of the problem are notified without any delay.

News
Article about our study with limbal stem cells

On the website of the Harvard Stem Cell Institute you will find the following news release about the ongoing clinical trial conducted by our daughter company RHEACELL in patients suffering from limbal stem cell deficiency: Restoring vision: A stem cell therapy for cornea regeneration reaches the clinical-trial stage.

Clinical Trial - EB

The international phase I/IIa clinical trial has been approved by the U.S. Food and Drug Administration (FDA) and several European competent national regulatory authorities. The medicinal drug product tested in this trial has recently been granted Orphan Drug designation from the FDA and the European Medicines Agency (EMA) for the treatment of EB.

Clinical Trial - LSCD

The international phase I/IIa clinical trial has been approved by the U.S. Food and Drug Administration (FDA) and the German regulatory authority (Paul Ehrlich Institute). The medicinal drug product tested in this trial has recently been granted Orphan Drug designation from the FDA and the European Medicines Agency (EMA) and Fast Track designation from the FDA for the treatment of LSCD.

Safety

In a comprehensive preclinical study program, safety and local tolerability of ABCB5+ MSCs following subcutaneous, intramuscular and intravenous application has been demonstrated (Tappenbeck et al., 2019).

Newsletter